Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

Fudan University285 enrolled

Overview

To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.

Study Type

OBSERVATIONAL

Enrollment

285

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. woman, age \> 18 years old 2. Diagnosed with HER2 +Metastatic Breast Cancer 3. Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy for at least one cycle, starting from 2013.09.01-2019.07.31 4. Available medical history Exclusion Criteria: * 1\. Incomplete medical history

Locations (1)

Biyun Wang, MD

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Overall survival

Time frame: 6 weeks

ORR

Objective Response Rate

Time frame: 6 weeks

Secondary Outcomes

Treatment Pattern

Choice of Treatment

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.